+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Filgrastim"

Filgrastim Biosimilars Global Market Report 2024 - Product Thumbnail Image

Filgrastim Biosimilars Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
Filgrastim - Biosimilar Insight, 2022 - Product Thumbnail Image

Filgrastim - Biosimilar Insight, 2022

  • Report
  • January 2022
  • 70 Pages
  • Global
From
Pegfilgrastim- Biosimilar Insight, 2022 - Product Thumbnail Image

Pegfilgrastim- Biosimilar Insight, 2022

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
  • 14 Results (Page 1 of 1)
Loading Indicator

Filgrastim is a type of oncology drug used to treat neutropenia, a condition in which the body does not produce enough white blood cells. It is a recombinant form of human granulocyte colony-stimulating factor (G-CSF), a naturally occurring hormone that stimulates the production of white blood cells. Filgrastim is used to reduce the risk of infection in patients undergoing chemotherapy or bone marrow transplantation. It is also used to treat severe chronic neutropenia, a rare condition in which the body does not produce enough white blood cells. Filgrastim is available in both injectable and subcutaneous forms. The injectable form is administered intravenously, while the subcutaneous form is injected under the skin. Filgrastim is typically administered once a day for five to seven days. Filgrastim is a widely used oncology drug, with many companies producing and marketing it. Some of these companies include Amgen, Teva Pharmaceuticals, Mylan, and Sandoz. Show Less Read more